AGILE THERAPEUTICS INC. overview

Thinking about buying stock in Agile Therapeutics, Nano-X Imaging, Eastside Distilling, Root Inc, or GigaCloud Technology? PR Newswire NEW YORK, Feb. 22, 2024 NEW YORK , Feb. 22, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGRX, NNOX, EAST, ROOT, and GCT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. AGRX:...

PRINCETON, NJ / ACCESSWIRE / November 22, 2023 / Agile Therapeutics, Inc. (NASDAQ:AGRX), the commercial-stage women's healthcare company, posted a 122% increase in third-quarter revenue year-over-year, driven by strong demand for TwirlaⓇ (levonorgestrel and ethinyl estradiol) transdermal system, its birth control patch. The company also reiterated its target for full-year 2023 revenue of at least $25 million and to be cash flow positive from operations in the first quarter of 2024. "In the...

PRINCETON, NJ / ACCESSWIRE / September 28, 2023 / Maxim Group , a major investment bank, conducts and publishes stock analysis through its Equity Research team. The team has a strong reputation in the industry; a host of major firms use its research. The firm's focus and area of expertise is in small and micro-cap companies, some of which are poised for growth. In a recent report , the research team at Maxim Group outlined why it has upgraded Agile Therapuetics Inc. (NASDAQ:AGRX) to a "buy"...

PRINCETON, NJ / ACCESSWIRE / August 17, 2023 / On August 9, Agile Therapeutics (NASDAQ:AGRX) released its second-quarter financial results, showing significant growth in revenue from its innovative weekly birth control patch, Twirla® (levonorgestrel and ethinyl estradiol), and a widening gross margin thanks to net revenue growth and decreasing operating expenses. "We set single-quarter record highs in demand, net revenue and factory sales, all while reporting another quarterly decrease in...

PRINCETON, NJ / ACCESSWIRE / July 19, 2023 / Agile Therapeutics, Inc.'s (NASDAQ:AGRX) partnership with Afaxys Pharma is expected to play a key role in propelling the women's healthcare company toward its $25-$30 million net annual revenue target for 2023. The companies teamed up last year to make Twirla® (levonorgestrel and ethinyl estradiol) transdermal system, Agile's low-dose contraceptive patch available to the more than 15,000 health centers that Afaxys serves. Community And Public Health...

PRINCETON, NJ / ACCESSWIRE / July 18, 2023 / This month, Agile Therapeutics, Inc. (NASDAQ:AGRX) announced partnerships with FPA Women's Health and vitaCare Prescription Services that will expand access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system, its low-dose weekly birth control patch. The news builds on earlier partnerships that have been steadily making the patch more available, including an agreement signed in August of last year making Twirla available on the Nurx...

PRINCETON, NJ / ACCESSWIRE / July 11, 2023 / - In June, President Biden issued an Executive Order on Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services . It directs the Secretaries of Health and Human Services (HHS), Labor and the Treasury to issue new guidance that ensures all contraceptives approved by the Food and Drug Administration (FDA) are covered without cost-sharing by private health insurance. The order also directs the departments to take...

PRINCETON, NJ / ACCESSWIRE / July 5, 2023 / H.C. Wainwright & Co, reiterated its buy rating on Agile Therapeutics, Inc. (NASDAQ:AGRX) this month, setting a price target of $12 per share. The $12 price target is based on the 1:50 reverse split and the $7.5 million raised in Agile's public offering in May. Despite challenges faced by the women's healthcare company, its patented weekly birth control patch has seen a steady increase in demand, and the company is leveraging key partnerships to expand...